Background: Despite the success of anti-vascular endothelial growth factors (anti-VEGFs),
currently, there is a need for highly effective compounds that can alleviate the burden of …

The three interacting components of the outer blood-retinal barrier are the retinal pigment
epithelium (RPE), choriocapillaris, and Bruch's membrane, the extracellular matrix that lies …

Background/Aim To assess visual acuity (VA) outcomes and antivascular endothelial growth
factor (anti-VEGF) treatment intensity in diabetic macular oedema (DMO). Methods …

Age-related macular degeneration (AMD) was described for the first time in the 1840s and is
currently the leading cause of blindness for patients over 65 years in Western Countries …

Currently, the treatment for ocular neovascular diseases, including diabetic macular edema
(DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal …

Abstract Purpose of Review Intravitreal anti-vascular endothelial growth factor (VEGF)
agents are used routinely in the management of neovascular conditions including …

Aging contributes to the risk of development of ocular diseases including, but not limited to,
Age-related Macular Degeneration (AMD) that is a leading cause of blindness in the United …

Topical drug delivery to the posterior segment of the eye is a very complex challenge.
However, topical delivery is highly desired, to achieve an easy-to-use treatment option for …

Diabetic retinopathy (DR) is a microvascular disease caused by poorly controlled blood
glucose, and it is a leading cause of vision loss in people with diabetes. In this review we …

Therapeutic modulation of vascular cell proliferation and migration is essential for the
effective inhibition of angiogenesis in cancer or its induction in cardiovascular disease. The …